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Abstract The aim of this study was to compare the efficacy
and retention rates of three biologics (abatacept, tocilizumab,
and etanercept) after switching from first-course anti-TNF
monoclonal antibody therapy. We performed a retrospective
multicenter study of 89 patients who underwent second-
course biologic therapy for 52 weeks after switching from
first-course anti-TNF monoclonal antibody therapy. Patients
at baseline had a mean age of 58.7 years, mean disease
duration of 9.8 years, and mean clinical disease activity index
(CDAI) of 22.4. There was no significant difference between
the three drugs, except in rheumatoid factor positivity. Reten-
tion rates for abatacept, tocilizumab, and etanercept treatment
at 52 weeks were 72.0, 89.5 and 84.6 %, respectively. The
evaluation of CDAI indicated no significant difference at
52 weeks among the three drugs. Discontinuation due to all
unfavorable causes did not significantly differ among the three
drugs in hazard ratio-based evaluations. Our results show that
patients treated with abatacept, tocilizumab, and etanercept
achieved a high response rate with no significant differences
in drug retention rates and clinical efficacy. These drugs
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represent good therapeutic options for patients with RA who
are refractory to anti-TNF monoclonal antibody therapy.
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Introduction
Rheumatoid arthritis (RA) is a chronic and systemic autoim-
mune inflammatory disease that clinically manifests as joint
pain and swelling [1]. In the past decade, treatment of RA has
improved significantly with the introduction of tumor necrosis
factor inhibitors (TNFi), which reportedly demonstrate high
efficacy [2–4]. However, these drugs have little or no effect in
about 30 % of treated patients, with two thirds demonstrating
moderate to high disease activity at 1 year post-treatment [5].
In clinical practice, switching biologics remains a difficult
issue. According to the European League Against Rheuma-
tism recommendations, patients who do not respond to initial
TNFi therapy should switch to a different TNFi or use a
different class of biologics (abatacept, rituximab, or toci-
lizumab) [6]. While some studies reported on the outcomes
of switching from TNFi to other biologics [7, 5, 8], no con-
sensus has been reached on the strategy of switching.
Loss of therapeutic efficacy is readily observed with anti-
TNF monoclonal antibodies (adalimumab and infliximab) in
patients receiving concomitant low-dose methotrexate (MTX)
due to immunogenicity-related issues [9–11]. This is one
factor leading to withdrawal from anti-TNF monoclonal anti-
body therapy. The dose of concomitantMTX in Japan is lower
compared to other countries [12], and switching from anti-
TNF monoclonal antibodies is often required. To this end, we
compared three drugs (abatacept, tocilizumab, and etanercept)
that are considered to exhibit low immunogenicity [13, 14, 2].
In this study, etanercept, a drug with proven efficacy, was
compared with abatacept and tocilizumab. In view of the
different characteristics of available TNFi, switching from an
anti-TNF monoclonal antibody to a TNF receptor fusion
protein (etanercept) may be helpful if initial treatment fails.
On the other hand, several new biologics with different mech-
anisms of action are now available (e.g., abatacept, rituximab,
and tocilizumab). Some reports have compared switching to
tocilizumab and abatacept [15, 16, 7]. Hyrich et al. reported
that when the first TNFi treatment fails, the best alternative is
to start on a different class of biologics [16]. However, there
are no reports to date comparing new biologics with
etanercept. Accordingly, this study aimed to compare patients
who switched to etanercept, abatacept, and tocilizumab from
first-course anti-TNF monoclonal antibody therapy.
Abatacept and tocilizumab are recently approved non-
TNFi biologics that are marketed for the treatment of RA.
Abatacept is the first member of a new class of biologics
which inhibit T-cell activation by binding to CD80/86 and
modulating its interaction with CD28. Based on this mecha-
nism, abatacept is expected to achieve clinical efficacy in
patients who respond inadequately or are naïve to other clas-
ses of biologics. Tocilizumab, a humanized monoclonal anti-
body against the IL-6 receptor, was approved in 2008 for use
in clinical practice in Japan. The efficacy of tocilizumab for
RA has been demonstrated in several clinical trials [14, 17] as
well as in actual practice [18, 19]. Both drugs show low
immunogenicity, with anti-drug antibody production rate of
2.3 % for abatacept and 2.5 % for tocilizumab [13, 14]. The
efficacy and safety of these drugs in patients who are naïve or
refractory to TNFi therapy have been demonstrated in several
randomized controlled clinical trials (RCTs) [20–23]. Howev-
er, controversy exists as to whether a different TNFi (e.g.,
etanercept) should be selected or other elements of the inflam-
matory process should be modified when switching from anti-
TNF monoclonal antibodies.
Patients may exhibit differential responses to the three
agents (abatacept, tocilizumab, and etanercept) upon
switching, although there is no direct evidence to support this.
The present study compared retention rates and clinical effi-
cacy of abatacept, tocilizumab, and etanercept switched from
first-course anti-TNF monoclonal antibody therapy based on
retrospectively registered observational data.
Materials and methods
Tsurumai Biologics Communication Registry
The Tsurumai Biologics Communication Registry
(TBCR) was developed in 2008 to explore the long-term
prognosis of biologics in clinical practice and consisted of
patients who were starting biologic treatments. Data were
collected prospectively from 2008 and retrospectively for
patients treated up to 2008 [24]. The present study includ-
ed all patients (n=89) who switched to abatacept, toci-
lizumab, or etanercept as a second biologic agent from
first-course anti-TNF monoclonal antibody due to inade-
quate efficacy from September 2010 to September 2011 at
Nagoya University Hospital or one of 12 other institutions
affiliated with the TBCR and were prospectively enrolled
in the TBCR. During the study period, we were able to
choose freely among the five biological DMARDs
(infliximab, etanercept, adalimumab, tocilizumab,
abatacept) at our discretion as a second-line as well as a
first-line biologic. All patients met the 1987 American
College of Rheumatology classification criteria for RA
and received abatacept, tocilizumab, or etanercept infu-
sions according to the drug label and Japan College of
Rheumatology guidelines for treatment. Patient anonymi-
ty was maintained during data collection, and the security
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of personal information was strictly controlled. This study
was approved by the Ethics Committee of the Nagoya
University Graduate School of Medicine.
Data collection
Data were retrospectively collected from clinical records. The
following demographic data were recorded at the initiation of
treatment (baseline, week 0): disease duration, concomitant
treatment (methotrexate [MTX] or prednisolone), joint dam-
age (Steinbrocker stage), and daily dysfunction (Steinbrocker
class). The following disease parameters were recorded at
baseline and at 24 and 52 weeks of treatment: tender joint
count (TJC) and swollen joint count (SJC) on 28 joints,
general health on a visual analog scale (GH-VAS), and serum
C-reactive protein (CRP) levels. Disease activity was evaluat-
ed at each time point using the 28-joint disease activity score
with CRP (DAS28-CRP) and the clinical disease activity
index (CDAI) which included data from the cited disease
parameters.
Statistical analysis
Demographic and disease characteristics were reported using
descriptive statistics. All results are expressed as mean±SD or
percentage. Student’s t-test was used for two-group compari-
sons and the chi-square test for categorical variables. The last
observation carried forward (LOCF) method was used in each
analysis. All statistical tests were two-sided, and significance
was defined as p<0.05. Drug continuation rates were estimat-
ed by plotting Kaplan–Meier curves and were compared using
log-rank test. Hazard ratios (HRs) for cause-specific drug
discontinuation were calculated using the Cox proportional
hazards model, adjusted for variables such as disease duration,
age, sex, and concomitant use of MTX and CDAI. All anal-
yses were performed with SPSS version 20.0.0 software (IBM
Corp., Armonk, NY, USA).
Results
Patients
We examined 89 patients who switched to abatacept, toci-
lizumab, and etanercept as a second biologic agent from first-
course anti-TNF monoclonal antibody therapy due to inade-
quate efficacy. Of these, 25 (28.1 %) had switched to
abatacept, 38 (42.7 %) had switched to tocilizumab, and 26
(29.2 %) had switched to etanercept.
Baseline characteristics of all patients are shown in Table 1,
categorized by the second biologic agent. Mean age was 58.7
±12.1 years, mean disease duration was 9.8±8.3 years, and
mean DAS28-CRP and CDAI were 4.6±1.2 and 22.4±11.0,
respectively. A significant difference was found in rheumatoid
factor positivity among the three drugs. No significant differ-
ences were found in factors reported to affect the effects of
biologics, including MTX use, MTX dose, and disease dura-
tion. In the present study, the rate of concomitant MTX use
was 78.7 %, with a mean dose of 7.4 mg/week.
Drug continuation rates
Drug continuation rates were analyzed with Kaplan–Meier
curves (Fig. 1). At 52 weeks, continuation rates for abatacept,
tocilizumab, and etanercept were 72.0, 89.5, and 84.6 %,
respectively (log-rank test, p=0.121), for discontinuation
due to all unfavorable causes (Fig. 1a). When classified ac-
cording to reasons for discontinuation, continuation rates at
52 weeks for abatacept, tocilizumab, and etanercept were
88.0, 97.1, and 90.5 % (log-rank test, p=0.374), respectively,
for discontinuation due to adverse events (Fig. 1b), and 82.6,
91.9, and 95.7 % (log-rank test, p=0.182), respectively, for
discontinuation due to inadequate efficacy (Fig. 1c). It should
be noted that discontinuation of tocilizumab due to adverse
events and discontinuation of etanercept due to inadequate
efficacy were low, although there was no significant differ-
ence. All drugs exhibited good retention rates.
Clinical efficacy
Figure 2 shows changes in tender joint counts, swollen joint
counts, GH-VAS, CRP, DAS28-CRP, and CDAI at 0, 24, and
52 weeks. The decline over time in TJC, SJC, GH-VAS, CRP,
DAS28-CRP, and CDAI significantly improved at all time
points. TJC and SJC showed similar improvements without
significant differences among the three drugs. GH-VAS was
clearly higher in abatacept-treated patients (44.2±27.3) com-
pared to others (tocilizumab, 23.9±23.0, p=0.004; etanercept,
24.8±20.8, p=0.007) at 24weeks, but there was no significant
difference at 52 weeks. GH-VAS decreased more gradually in
abatacept-treated patients. CRP levels were clearly lower with
tocilizumab compared to abatacept at 24 weeks (tocilizumab,
0.16±0.85; abatacept, 0.87±1.16; p=0.002) and 52 weeks
(tocilizumab, 0.21±0.87; abatacept, 0.91±0.98; p=0.001).
DAS28-CRP showed no difference among the three drugs at
24 weeks but was lower with tocilizumab compared to
abatacept at 52 weeks (tocilizumab, 2.51±1.12; abatacept,
3.22±1.11; p=0.016). As shown in Fig. 3, all three drugs
demonstrated good efficacy at 52 weeks in the evaluation
based on CDAI. Remission rates and percentages of subse-
quent low disease activity for abatacept, tocilizumab, and
etanercept were 20.7, 28.6, and 20.6 %, respectively, and
49.8, 68.2, and 70.6 %, respectively.
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Multivariate analysis
We calculated HRs for cause-specific drug discontinuation
using multivariate Cox proportional HR analysis (Table 2)
adjusted by disease duration, age, sex, concomitant MTX
use, and CDAI. Discontinuation due to all unfavorable causes
did not significantly differ among abatacept, tocilizumab, and
etanercept, although discontinuation of tocilizumab due to
adverse events and discontinuation of etanercept due to inad-
equate efficacy tended to be less common. There was no
significant difference in inadequate efficacy and adverse
events across the three drugs.
Discussion
The recent introduction of two new biologics, abatacept and
tocilizumab, into the market represents interesting new thera-
peutic opportunities for patients with RAwho are resistant to
TNFi. In the present study, no apparent difference in terms of
efficacy was observed among abatacept, tocilizumab, and
etanercept after switching from anti-TNF monoclonal
antibodies.
In general, when patients respond poorly to the first TNFi
after 3 to 4 months, switching to a different biologic agent is
considered [6]. If the secondary loss of efficacy is due to anti-
drug antibodies, switching to a second TNFi might prove
effective [16]. In many cases, the first treatment is
discontinued due to immunogenicity-related problems associ-
ated with the concomitant use of low-dose MTX. In such
cases, the biologics with low immunogenicity are useful.
Etanercept does not require concomitant MTX necessarily
and could thus demonstrate the expected efficacy [2]. In
contrast, if the secondary loss of efficacy is due to TNF no
longer being the primary cytokine, switching to other classes
of biologics will be required. Whenever possible, the
switching of biologics should be decided based on the cause
of secondary loss of efficacy; however, there is currently no
method to determine this. Moreover, there is no consensus
regarding the strategy of switching biologics.
Table 1 Baseline characteristics of patients with rheumatoid arthritis who switched from anti-TNF monoclonal antibodies
Overall (n=89) Abatacept (n=25) Tocilizumab (n=38) Etanercept (n=26) p value
Age (year) 58.7±12.1 62.8±9.3 56.7±12.4 57.5±13.3 0.315
Sex (% female) 82 80 78.9 88.5 0.593
Disease duration (year) 9.8±8.3 11.4±9.5 7.9±6.1 11.0±9.6 0.207
Stage (I/II/III/IV, %) 19.1/21.3/24.7/32.6 20.0/20.0/24.0/36.0 19.4/22.2/33.3/25.0 19.2/23.1/15.4/42.3 0.627
Class (I/II/III/IV, %) 13.5/50.6/29.2/4.5 12.0/52.0/36.0/0 16.8/52.8/27.8/2.8 11.5/50.0/26.9/11.5 0.453
RF positive (%) 82.9 70.6 78.6 96 0.002
Previous biological DMARDs (%)
Adalimumab 37.1 60 26.3 30.8
Infliximab 62.9 40 73.7 69.2
MTX use (%) 78.7 80 73.7 84.6 0.567
MTX dose (mg/week)a 7.4 7.5 7.3 7.8 0.716
Oral steroid use (%) 58.4 64 59.5 53.8 0.760
Oral steroid dose (mg/day)a 4.2 3.8 4 4.8 0.433
MMP-3 (ng/mL) 257.0±235.2 217.1±190.0 317.4±271.6 183.9±129.0 0.371
SJC, 0–28 5.4±4.8 5.9±5.6 5.7±4.9 4.7±3.7 0.546
TJC, 0–28 6.4±5.6 5.3±4.1 6.0±5.7 7.9±6.6 0.439
ESR (mm/h) 53.1±27.1 57.4±32.1 51.1±24.9 53.0±26.4 0.475
CRP (mg/dL) 2.6±2.6 1.7±1.9 2.9±2.8 3.0±2.9 0.374
GH-VAS 0–100 mm 54.1±22.9 53.7±25.2 53.9±22.4 54.6±22.3 0.514
DAS28-ESR 5.3±1.2 5.2±1.2 5.3±1.2 5.4±1.3 0.267
DAS28-CRP 4.6±1.2 4.4±1.1 4.7±1.2 4.8±1.1 0.266
CDAI 22.4±11.0 21.2±11.0 22.4±11.1 23.5±11.2 0.266
SDAI 24.8±11.6 23.1±11.3 24.7±11.5 26.4±12.3 0.335
Data are presented as mean±SD, unless otherwise indicated
Stage Steinbrocker stage, Class Steinbrocker class, RF rheumatoid factor, MTX methotrexate, MMP-3 matrix metalloproteinase-3, SJC swollen joint
count, TJC tender joint count, ESR erythrocyte sedimentation rate, CRP C-reactive protein, GH-VAS general health visual analog scale, DAS28 disease
activity score in 28 joints, CDAI clinical disease activity index, SDAI simplified disease activity index
aMean among patients receiving the drug
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The present observational study was based on data from a
multicenter registry regarding the clinical efficacy of
abatacept, tocilizumab, and etanercept in patients with RA in
whom anti-TNF monoclonal antibody therapy previously
failed. Therefore, the present results reflect treatment out-
comes of the “real world.”
Several studies have reported on switching from TNFi to
other biologics. One meta-analysis revealed no difference in
ACR50 response to rituximab, tocilizumab, abatacept, and
golimumab when switched from TNFi [15]. According to
the Danish DANBIO study, 48-week retention rates of
abatacept and tocilizumab after switching from TNFi were
54 and 64 %, respectively [7]. The retention rates in our study
were better (68.0 % for abatacept and 89.5% for tocilizumab).
In the DANBIO study, the mean DAS28-CRP at 48 weeks
was 3.3 for abatacept and 2.5 for tocilizumab, which were
comparable to our results at 52 weeks (abatacept, 3.22±1.11;
tocilizumab, 2.51±1.12). In addition, 48-week remission rate
in the DANBIO study was 26 % for abatacept and 58 % for
tocilizumab, which are better or almost the same as our results
(17.4 and 55.6 %, respectively). The ATTAIN study, which
examined patients who switched from TNFi to abatacept,
reported the percentages of low disease activity and remission
to be 24.2 and 13.9 %, respectively [25]. Compared to these,
the percentages of low disease activity and remission in the
present study were better (34.8 and 17.4 %, respectively). In
the RADIATE study, DAS28 remission rate at 24 weeks
(DAS28-CRP 2.6) was 30.1 % in patients who switched from
TNFi to tocilizumab [20], compared to 50.0 % in the present
study. This difference might be attributed to low DAS28CRP
values at baseline and the short disease duration of 7.9±
6.1 years in our study. As for patients who switched to
etanercept from TNFi, the RADIUS study [26] reported a
52-week retention rate of 74 % in comparison to 84.6 % in
our study. Taken together, our results are in good agreement
with previous reports.
It should be emphasized that, in the present study, response
rates and survival could not be compared among abatacept,
tocilizumab, and etanercept due to the non-randomized, retro-
spective design. However, slight differences in clinical re-
sponses and disease activity (as judged by DAS28 CRP)
among the three drugs appeared to be primarily due to the
large decrease of CRP and ESR in tocilizumab-treated pa-
tients. Given that tocilizumab is an IL-6 antagonist and since
IL-6 enhances the formation of CRP and ESR, our findings
raise the question as to whether DAS28 is a valid tool for
assessing disease activity for drugs that affect CRP and ESR.
When evaluating tocilizumab, we believe that CDAI would
serve as a useful tool since it does not involve CRP and ESR.
In the present study, significant differences were found in CRP
and DAS28-CRP when abatacept and tocilizumab were com-
pared; however, as shown in Fig. 2f, there was no significant
difference among the three drugs in terms of CDAI. The
Fig. 1 Patient retention in abatacept, tocilizumab, and etanercept treat-
ment. Kaplan–Meier curves of treatment continuation rates among pa-
tients with rheumatoid arthritis over 52 weeks of treatment. a Discontin-
uation due to all unfavorable causes. b Discontinuation due to adverse
events. c Discontinuation due to inadequate efficacy
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efficacy of the three drugs was found to be similar in the
evaluation without CRP. In addition, the efficacy of toci-
lizumab was unchanged when the effects of CRP negativity
was excluded.
In the present study, the three drugs showed no difference
in therapeutic effects in patients with inadequate responses to
anti-TNF monoclonal antibodies. In other words, abatacept
and tocilizumab, which were found to be effective when
switched from an anti-TNF monoclonal antibody, would offer
good therapeutic options, as would etanercept in these pa-
tients. These biologics should be selected based on consulta-
tion with the patient regarding the method of administration
(intravenous/subcutaneous injection) and dosing interval.
Limitations of this study include the small number of
patients treated with each biologic agent. In the present study,
it was necessary to set the study period after September 2010
as this was the year when abatacept was released in Japan. In
addition, the number of patients requiring switching of med-
ications was low since the long-term efficacy and safety of
anti-TNF agents had been established. Nonetheless, use of the
Fig. 2 Overall clinical efficacy of switching biologics in patients with
rheumatoid arthritis. Mean values for a swollen joint count (SJC), b
tender joint count (TJC), c general health on a visual analog scale (GH-
VAS), d C-reactive protein (CRP), e 28-joint disease activity score with
CRP (DAS28-CRP), and f clinical disease activity index (CDAI). ABT
abatacept, TCZ tocilizumab, ETN etanercept. *P<0.05 tocilizumab vs.
abatacept. **P<0.01 tocilizumab vs. abatacept. †P<0.05 etanercept vs.
abatacept. ††P<0.01 etanercept vs. abatacept
Fig. 3 Clinical disease activity index (CDAI) with second-course bio-
logics (0, 24, and 52 weeks). ABT abatacept, TCZ tocilizumab, ETN
etanercept, HDA high disease activity (CDAI>22), MDA moderate dis-
ease activity (10<CDAI≤22), LDA low disease activity (CDAI≤10).
Remission (CDAI≤2.8)
Table 2 Hazard ratios for discontinuation of the three drugs due to
specific causes
Etanercept Tocilizumab Abatacept
(reference) HR (95 % CI) HR (95 % CI)
All unfavorable
causes
1 0.58 (0.13–2.66) 1.21 (0.33–4.51)




Adverse events 1 0.28 (0.27–2.82) 0.77 (0.13–4.42)
Adjusted by sex, age, concomitant use of methotrexate, disease duration,
and clinical disease activity index
HR hazard ratio, CI confidence interval
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TBCR with over 2,000 cases enabled us to collect data for the
present study. Given that the sample size might be insufficient
to obtain strong statistical power, further studies will be nec-
essary to reach the definite conclusion, yet our findings sug-
gest nomajor differences among the three classes of biological
DMARDs in terms of clinical efficacy after failure of first-
course anti-TNF monoclonal antibody treatment. Additional-
ly, given the retrospective design of the present study, drug
selection was not randomized. Because of the bias of attend-
ing physicians, the number of cases that switched between
anti-TNF monoclonal antibodies was quite low. As such, we
were unable to evaluate in detail the switching between TNFi.
Further evaluation is required for those who switch from anti-
TNF monoclonal antibodies to another anti-TNF monoclonal
antibody. Another limitation was the lack of data regarding the
impact on structural damage (i.e., radiographic progression).
These points should be addressed in the future.
In summary, we conclude that patients treated with either
abatacept, tocilizumab, or etanercept can achieve a high re-
sponse rate and that these biologics represent good therapeutic
options in patients with RAwho are refractory to first-course
anti-TNF monoclonal antibody therapy. Moreover, the three
biologics showed no significant difference in retention rate
and efficacy. Further investigation to compare second-course
anti-TNF monoclonal antibodies with the three drugs is need-
ed to promote efficient drug selection when patients are
switched from anti-TNF monoclonal antibodies.
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